LakePharma Inc., a U.S.-based biologics contract research, development and manufacturing organization (CRDMO), and New Brunswick-based NJ Biopharmaceuticals LLC, a contract research organization (CRO) providing integrated chemistry and biology services, announced on Tuesday the formation of a strategic alliance to offer streamlined antibody-drug conjugate (ADC) development solutions for the biotechnology and pharmaceutical sectors.
LakePharma is a supplier of novel antibodies for more than 10 years and NJ Bio has expertise in linker-payload synthesis and bioconjugation to create ADCs.
Under the terms of the alliance, LakePharma will manufacture and provide antibodies as starting materials for ADC development carried out by NJ Bio in a single workflow for clients, making therapeutic ADC manufacturing from initial antibody discovery to the production of the drug conjugates more efficient, both in time and expense.
“LakePharma is an expert in antibody discovery, engineering, and production while NJ Bio is a pioneer in performing chemistries with antibodies. An alliance between these two companies makes perfect sense. Our partnership with NJ Bio allows us to provide a one-stop experience for our contract research partners,” said Hua Tu, chief executive officer and chairman of LakePharma.
Nareshkumar Jain, president and CEO of NJ Bio, said: “This alliance will expand and add value to the ADC services we currently provide to our clients, creating cost-effective solutions through the provision of complementary service offerings between NJ Bio and LakePharma.”